Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status / 中华肿瘤杂志
Chinese Journal of Oncology
; (12): 273-276, 2013.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-284193
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the correlation of clinical effect and prognosis between patients with metastatic colorectal cancer (mCRC) and different K-ras status.</p><p><b>METHODS</b>The clinical characteristics, chemotherapeutic regimens and survival of 153 mCRC patients with different K-ras status were analyzed retrospectively.</p><p><b>RESULTS</b>The median overall survival (OS) in patients without K-ras mutation were 31.7 months, significantly longer than 21.3 months in the patients with K-ras mutation (P = 0.037). The median progression-free survival (PFS) and OS in patients who received chemotherapy followed by anti-EGFR antibody treatment were 11.5 and 39.3 months, respectively, significantly longer as compared with the PFS and OS in those received chemotherapy in combination with anti-EGFR antibody concomitantly (5.7, P = 0.02, and 28.7 months, P = 0.034, respectively).</p><p><b>CONCLUSIONS</b>K-ras status is a prognostic biomarker for mCRC patients treated with anti-EGFR antibody. The combination settings of anti-EGFR in combination with chemotherapy may improve survival of mCRC patients with wild-type K-ras status.</p>
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Compostos Organoplatínicos
/
Patologia
/
Cirurgia Geral
/
Terapêutica
/
Camptotecina
/
Neoplasias Colorretais
/
Taxa de Sobrevida
/
Estudos Retrospectivos
/
Seguimentos
/
Genes ras
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
/
Fatores de risco
Limite:
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Chinese Journal of Oncology
Ano de publicação:
2013
Tipo de documento:
Artigo